Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial

RCT (n=151) found landiolol resulted in significantly more patients with sepsis-related tachyarrhythmia achieving a heart rate of 60–94 bpm at 24 h vs. conventional sepsis therapy group (55% vs 33%, difference 23.1% (95% CI 7.1–37.5; p=0.0031).

Source:

The Lancet Respiratory Medicine